Skip to content
HowShorted

Protara Therapeutics, Inc. short interest in 2024

In 2024, Protara Therapeutics, Inc.'s disclosed short interest ran from 0.65% of shares outstanding on 12 Jan 2024 to 24.72% on 31 Dec 2024, a change of +24.07 percentage points. The year's high was 26.21% on 13 Dec 2024 and its low 0.52% on 15 Feb 2024, averaging 9.17% across 16 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.30 days on 15 Oct 2024. Full history: Protara Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Protara Therapeutics, Inc. in 2024

2024 in figures

Start of year
0.65% (12 Jan 2024)
End of year
24.72% (31 Dec 2024)
Change
+24.07 pp
High
26.21% (13 Dec 2024)
Low
0.52% (15 Feb 2024)
Average
9.17%
Highest days to cover
22.30 (15 Oct 2024)
SEC filings marked
8

Every report in 2024

Protara Therapeutics, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20240.65%1.07
31 Jan 20240.78%1.64
15 Feb 20240.52%1.00
29 Feb 20240.69%1.00
15 Mar 20240.54%1.0010-K filed, results (8-K)
28 Mar 20240.57%1.00
15 Aug 20249.11%10.5110-Q filed, results (8-K), 10-Q filed, results (8-K)
30 Aug 20249.91%11.46
13 Sep 202410.20%10.69
30 Sep 202410.40%16.71
15 Oct 202411.24%22.30
31 Oct 202413.27%10.71
15 Nov 202413.21%15.0210-Q filed, results (8-K)
29 Nov 202414.62%18.53
13 Dec 202426.21%1.00
31 Dec 202424.72%7.46

See also: Protara Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.